Testosterone Therapy in Men with Organ-Confined Gleason 6-7 Prostate Cancer After Radical Prostatectomy

Carolyn A. Salter, MD, a fellow in male sexual and reproductive medicine at Memorial Sloan Kettering Cancer Center, discusses a retrospective data study she and her team conducted on the effects of testosterone therapy in post-prostatectomy men. She first notes the history of testosterone therapy in men with prostate cancer, observing that the results of older studies resulted in the withholding of testosterone from men with prostate cancer. Dr. Salter then details her study, which examined testosterone-deficient men with organ-confined Gleason 6-7 prostate cancer who had undergone radical prostatectomy and had an undetectable PSA level. The men were monitored 2-4 weeks after testosterone therapy initiation, as well as 3-4 months later to check for improvement. They were then followed-up through 38 months, with the study finding that there was no significant risk of biochemical recurrence in these men.

Read More